A Comprehensive Meta-Analysis of Pharmacological Interventions for Rheumatoid Arthritis: Efficacy and Safety Profile

Efficacious pharmacological intervention is required in the management of rheumatoid arthritis (RA); thus, it is a comprehensive autoimmune arthritis disorder causing synovial inflammation and joint damage. This meta-analysis evaluates the efficacy and safety profiles of csDMARDs, bDMARDs, tsDMARDs, and Stephania Tetrandra Derivatives based on a systematic review of five studies (2008- 2025; n = 6,800 patients). Included were RCTs, observational studies, and meta-analyses from PubMed, Embase, and the Cochrane Library, focusing on outcomes such as DPS28 remission, HAQ-DI scores, and adverse events in which csDMARDs (e.g., PGA): Achieved DAS28 remission in 40% to 50% of early RA patients.

In bDMARDs (e.g., TNF and IL-6 inhibitors), this was almost 60% to 70% in refractory RA for low disease activity. While PGA remains first-line for early RA, biologics are best for refractory disease. JAK inhibitors should be used cautiously in those at moderate to high risk. Pharmacological Interventions do appear to have some advantages and reduced GI side effects, warranting further studies on using it as an adjunct and. This synthesis delineates the trade-off between efficacy and safety in RA therapeutics, thereby advocating regimen selections according to risk factors unique to the patient.